Results 141 to 150 of about 79,448 (358)

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Beyond Basic Needs: Social Support and Structure for Successful Offender Reentry [PDF]

open access: yes, 2014
Barriers to successful reentry have long been identified as impeding an offender’s ability to successfully reenter society upon release from incarceration. As a result, research has long examined what shared obstacles the majority of offenders often face
Denney, Andrew S.   +2 more
core   +1 more source

Potency of active compounds extract of soursop leaves (Annona muricata) as a candidate for cervical cancer drug in Silico [PDF]

open access: diamond
Moh. Royhan Afnani   +4 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

"Phederalism": The Regulation of Pharmacy Compounding and Two Years in the Regulatory Turf War Between Pharmacy and the Food and Drug Administration [PDF]

open access: yes, 2012
Pharmacy has long been considered among the most popular of professions, with pharmacists consistently topping surveys of whom Americans consider the most honest and ethical professionals. Pharmacy is also one of the most regulated professions.
Fairfax, Roger A.
core  

A compound-target pairs dataset: differences between drugs, clinical candidates and other bioactive compounds [PDF]

open access: gold
Anna Lina Heinzke   +6 more
openalex   +1 more source

The European Lead Factory: An updated HTS compound library for innovative drug discovery

open access: hybrid, 2021
Herman van Vlijmen   +3 more
openalex   +1 more source

The Brazilian Compound Library (BraCoLi) Database: A Brazilian Repository of Chemical and Biological Information for Drug Design [PDF]

open access: gold, 2021
Gabriel Corrêa Veríssimo   +6 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Smart Formulation: AI-Driven Web Platform for Optimization and Stability Prediction of Compounded Pharmaceuticals Using KNIME

open access: yesPharmaceuticals
Background/Objectives: Smart Formulation is an artificial intelligence-based platform designed to predict the Beyond Use Dates (BUDs) of compounded oral solid dosage forms.
Artur Grigoryan   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy